Kalbe Genexine Biologics

Kalbe Genexine Biologics is a clinical-stage biotechnology company focused on bringing biopharmaceutical medical innovations to markets outside the United States/Canada, Western Europe, and China. The business model revolves around licensing novel biologics and selecting biosimilars in the fields of oncology and highly specialized treatments (typically pre-IND or early clinical stage), with the aim of obtaining licenses in target regions after completing clinical development as well as securing regulatory and reimbursement approvals. Currently, platforms of interest include Fc fusion proteins, antibodies, bispecifics, ADCs, cell therapies, and therapeutic vaccines. The company is backed by Asian pharmaceutical giants Kalbe (market value of $5.5 billion) and Genexine (market value of $1.3 billion), as well as the U.S.-based private equity giant General Atlantic (AUM of $78 billion).